GPs 0193

Drug Profile

GPs 0193

Alternative Names: Navin

Latest Information Update: 19 May 1999

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antivirals
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Leukaemia
  • Discontinued HIV-1 infections

Most Recent Events

  • 19 May 1999 Discontinued-I for HIV-1 infections in USA (IV)
  • 02 Sep 1998 Profile reviewed
  • 31 Aug 1998 No-Development-Reported for Leukaemia in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top